Use of 3-carboxy-n-ethyl-n,n-dimethylpropan-1-ammonium or a pharmaceutically acceptable salt thereof in the prevention and treatment of diabetes
Patent Information
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- GRINDEKS
- Publication Date
- 2018-03-02
Smart Images

Figure 1 
Figure 2
Abstract
Description
technical field
[0001] The present invention relates to 3-carboxy-N-ethyl-N,N-dimethylpropan-1-ammonium or a pharmaceutically acceptable salt thereof for preventing and treating diabetes. Examples of pharmaceutically acceptable salts of 3-carboxy-N-ethyl-N,N-dimethylprop-1-ammonium are: 3-carboxy-N-ethyl-N,N-dimethylpropane- 1-Ammonium hydrogen fumarate and 3-carboxy-N-ethyl-N,N-dimethylprop-1-ammonium dihydrogen phosphate. Background technique
[0002] It is known that 3-carboxy-N,N,N-trimethylpropan-1-ammonium (GBB) is mainly a biological precursor of carnitine, a key molecule regulating myocardial energy metabolism. It was initially characterized as a toxic substance that accelerates respiration, causes salivation and lacrimation, mydriasis, vasoconstriction and diastolic cardiac arrest (LINNEWEH W. Gamma-Butyrobetain, Crotonbetain und Carnitin im tierischen Stoffwechsel. Hoppe-Seylers Zeitschrift fur physiologische Chemie. 1929, vol. 181, p. 42-53). In subsequent publ...